Skip to main content

Advertisement

Fig. 1 | Diabetology & Metabolic Syndrome

Fig. 1

From: Aliskiren effect on non-alcoholic steatohepatitis in metabolic syndrome

Fig. 1

Body weight (a); hepatic weight (b); hepatic total fat (c); ALT dosage (d); AST dosage (e); plasma glucose (f); plasma insulin (g); total cholesterol (h) and triglycerides (i) deposition in the liver in the control group (C); diabetic and high fat diet mice (HDC); diabetic and high fat diet mice treated with aliskiren (HDA). *P < 0.05, C × HDC; P < 0.05, HDC × HDA. (n = 4–6 mice per group)

Back to article page